Skip to main content
. 2020 Sep 15;11:4615. doi: 10.1038/s41467-020-18399-4

Fig. 5. The pharmacokinetics, biodistribution and in vivo antitumour effect of BAQ ONNs.

Fig. 5

a The plasma concentration-time profiles of DiD-loaded BAQ ONNs and free DiD after intravenous injection; data are mean values ± SD; n = 3. b In vivo and ex vivo biodistribution of BAQ13 NPs in mice bearing HT29 tumours at 24 h post injection. c Quantitative fluorescence intensity of tissues obtained at 12 and 24 h post injection; data are mean values ± SD; n = 3. d MIA PaCa-2 tumour growth curves in mice that were treated as indicated every 3 days; data are mean values ± SD; n = 6 tumours per group. e Body weight of mice during the treatment; data are mean values ± SD; n = 6 mice per group. f Weight of harvested tumours at the end of the treatment; data are mean values ± SD; n = 6 tumours per group. gj Representative H&E (g), IHC (h), immunoblotting (i) and TEM (j) results of tumours that were harvested at the end of treatments; Blots in i were from three individual tumours of each group; purple arrows in j: autophagic vesicles; experiments in gj were all repeated three times independently. All statistical p values were calculated by one-way ANOVA with the Tukey’s multiple comparison test; *p < 0.05; ****p < 0.0001.